Clinical trials: NSCLC Stage II
Lung Cancer
Collecting and Analyzing Tissue Samples From Patients Undergoing Surgery for Non-Small Cell Lung Cancer
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that may occur in RNA and identify biomarkers related to cancer.
- Trial name
- NCT00897117
- Testing
- gene expression analysis, microarray analysis, protein expression analysis
- Where
- 3 sites in United States
- Volunteers
- 4,000 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Non-small Cell Lung Cancer
Study of BMS-275183 in Patients With Pretreated Locally Advanced or Metastatic NSCLC (Non Small Cell Lung Cancer)
BMS-275183 given orally twice weekly to patients pretreated for locally advanced or metastatic NSCLC will show anti-tumor activity in any of the 3 separate cohorts of the patients enrolled: Cohort I: Patients previously treated…
- Trial name
- NCT00359450
- Testing
- BMS-275183 (oral taxane)
- Where
- 30 sites in United States, Belgium and 6 more
- Volunteers
- 186 people
- Sponsor
- Bristol-Myers Squibb
Adenocarcinoma of the Lung
Study of Vintafolide (MK-8109, EC145) in Participants With Progressive Adenocarcinoma of the Lung (MK-8109-008, EC-FV-03)
This is a Phase II clinical trial evaluating the benefit from therapy with vintafolide in participants with progressive adenocarcinoma of the lung.
- Trial name
- NCT00511485
- Testing
- Vintafolide, Etarfolatide
- Volunteers
- 43 people
- Sponsor
- Endocyte
Non-small Cell Lung Cancer
Safety and Effect of Pertuzumab in Patients With Advanced Non-Small Cell Lung Cancer, Which Has Progressed After Prior Chemotherapy
The purpose of this study is to determine if the study drug pertuzumab is effective in treating patients with advanced lung cancer that has recurred following prior chemotherapy.
- Trial name
- NCT00063154
- Testing
- Pertuzumab
- Where
- 8 sites in United States
- Volunteers
- 51 people
- Sponsor
- Genentech, Inc.
Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung
A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma
The goal of this clinical trial is to determine clinical advantages for LP-300 in combination with carboplatin and pemetrexed in the never smoker patient population.
- Trial name
- HARMONIC (NCT05456256)
- Testing
- LP-300, Pemetrexed, Carboplatin
- Where
- 16 sites in United States, Japan and 1 more
- Volunteers
- 90 people
- Sponsor
- Lantern Pharma Inc.
Carcinoma, Non-Small Cell Lung
Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer
This is a phase II trial of durvalumab and tremelimumab in combination of platinum-based chemotherapy. Patients with stage IV Non-Small-Cell-Lung Cancer (NSCLC) with human immunodeficiency virus (HIV) infection will be eligible.
- Trial name
- NCT04499053
- Testing
- Durvalumab, Tremelimumab
- Where
- 4 sites in United States
- Volunteers
- 18 people
- Sponsor
- Georgetown University
Resectable Lung Non-Small Cell Carcinoma
A Study of Adebrelimab in Combination with Chemo with or Without Bevacizumab Neoadjuvant Therapy for Resectable NSCLC
This is a prospective, multicenter, randomized, uncontrolled Phase II study to assess the efficacy and safety of adebrelimab in combination with chemotherapy with or without bevacizumab for the treatment of resectable Stage…
- Trial name
- NCT06775275
- Testing
- Adebellizumab, Bevacizumab, Platinum-based chemotherapy
- Where
- China
- Volunteers
- 60 people
- Sponsor
- The First Affiliated Hospital of Guangzhou Medical University
Non-small Cell Lung Cancer
A Study Evaluates the Safety and Efficacy of WX-0593 in ALK -Positive, or ROS1-positive Non-small Cell Lung Cancer
The purpose of the study is to evaluate safety and efficacy of WX-0593 oral tablets in ALK -positive, or ROS1-positive non-small cell lung cancer (NSCLC)
- Trial name
- NCT04641754
- Testing
- WX-0593 Tablets
- Where
- 41 sites in China
- Volunteers
- 176 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Non Small Cell Lung Cancer
Surgery for Early Lung Cancer With Preoperative Erlotinib (Tarceva): A Clinical Phase II Trial (SELECT)
2.5 Rationale for preoperative erlotinib therapy Erlotinib is the only EFGR tyrosine kinase inhibitor to demonstrate a survival advantage and symptom improvement in a large phase III trial after failure of chemotherapy in…
- Trial name
- SELECT (NCT00462995)
- Testing
- Erlotinib
- Where
- 2 sites in Canada
- Volunteers
- 25 people
- Sponsor
- University Health Network, Toronto
Carcinoma, Non-Small-Cell Lung
Osimertinib In EGFR Mutant Lung Cancer
This research study is studying a targeted therapy as a possible treatment for Non-Small Cell Lung Cancer (NSCLC) with an EGFR mutation. The names of the study drug involved in this study is: Osimertinib (Tagrisso)
- Trial name
- NCT03586453
- Testing
- Osimertinib
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Dana-Farber Cancer Institute
Leptomeningeal Metastasis
Intrathecal Pemetrexed for Leptomeningeal Metastasis From Lung Adenocarcinoma That Progressed After Osimertinib.
Pemetrexed is one of the first-line chemotherapeutic agents for non-squamous non-small cell lung cancer (NSCLC). Since 2017, intrathecal pemetrexed has shown good efficacy for patients with leptomeningeal metastases from NSCLC.
- Trial name
- NCT06296745
- Testing
- Pemetrexed
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Guangzhou Medical University
Non-small Cell Lung Cancer
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
Beamion LUNG-3 study evaluates whether zongertinib, an oral HER2-targeted treatment, can improve outcomes compared with standard adjuvant treatment in adults with completely resected Stage II-IIIB non-small cell lung cancer…
- Trial name
- NCT07195695
- Testing
- Zongertinib, Pembrolizumab, Atezolizumab
- Where
- 202 sites in United States, Argentina and 26 more
- Volunteers
- 400 people
- Sponsor
- Boehringer Ingelheim
NSCLC
Carboplatin Plus Gemcitabine for Elderly Patients With Stage IV NSCLC
The investigators propose to study the safety and efficacy of the combination of Carboplatin plus Gemcitabine in a Phase I/II trial of elderly subjects with non-small cell lung cancer.
- Trial name
- NCT02175381
- Testing
- Carboplatin, Gemcitabine
- Where
- 5 sites in Greece
- Volunteers
- 69 people
- Sponsor
- Hellenic Oncology Research Group
NSCLC
Penpulimab Combined With Anlotinib in Neoadjuvant Treatment of Resectable Non-small Cell Lung Cancer
Neoadjuvant therapy with penpulimab combined with anlotinib;with surgery within 4-6 weeks after drug withdrawal;Adjuvant therapy within 4-12 weeks after surgery
- Trial name
- pcwaintrl (NCT05387109)
- Testing
- penpulimab combined with anlotinib
- Volunteers
- 41 people
- Sponsor
- Tang-Du Hospital
Tumors With Aberrations in ALK or ROS1
Ceritinib (LDK378) for Patients Whose Tumors Have Aberrations in ALK or ROS1 (SIGNATURE)
The purpose of this signal seeking study was to determine whether treatment with ceritinib demonstrated sufficient efficacy in select pathway-activated solid tumors and/or hematologic malignancies to warrant further study.
- Trial name
- SIGNATURE (NCT02186821)
- Testing
- Ceritinib
- Where
- 21 sites in United States
- Volunteers
- 47 people
- Sponsor
- Novartis Pharmaceuticals
Non-Small-Cell Lung Carcinoma
Study of OSI-774 (Tarceva) in Previously Untreated Elderly Lung Cancer Patients
The primary purpose of this study is to determine whether the drug OSI-774 is less toxic and potentially as good as or better than standard chemotherapy drugs, when given to subjects with non-small cell lung cancer, who are 70…
- Trial name
- NCT00137800
- Testing
- OSI-774 (Tarceva)
- Where
- 2 sites in United States
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- Dana-Farber Cancer Institute
Non-Small Cell Lung Cancer
Phase II Study Investigating the Combination of Encorafenib and Binimetinib in BRAF V600E Mutated Chinese Patients With Metastatic Non-Small Cell Lung Cancer
This is a phase 2, multicenter, single-arm study with a safety lead-in to investigate the efficacy, safety and pharmacokinetics of encorafenib 450 mg once daily (QD) in combination with binimetinib 45 mg twice daily (BID)…
- Trial name
- OCEANII (NCT05195632)
- Testing
- Encorafenib, Binimetinib
- Where
- 34 sites in China, Taiwan
- Volunteers
- 63 people
- Sponsor
- Pierre Fabre Medicament
Lung Cancer
S0709: Erlotinib With or Without Carboplatin and Paclitaxel in Stage IIIB or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor…
- Trial name
- NCT00661193
- Testing
- carboplatin, erlotinib hydrochloride, paclitaxel
- Where
- 124 sites in United States
- Volunteers
- 59 people
- Sponsor
- SWOG Cancer Research Network
EGFR Mutant NSCLC and Platinum Resistant Ovarian Cancer
A Study of IBI363 Combination Therapy in Participants With Advanced Solid Tumors
CIBI363A203, a Phase 2 study to evaluate the safety, tolerability and preliminary efficacy of IBI363 combined with IBI305 (a bevacizumab biosimilar) in participants with advanced malignancies conducted in China.
- Trial name
- NCT07124793
- Testing
- IBI363+IBI305
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
NSCLC
A Prospective Phase II Clinical Trial Evaluating the Efficacy and Safety of Adebrelimab in Combination With Trastuzumab Rezetecan for Patients With Stage III Unresectable HER2-Positive NSCLC
This is a single-arm, open-label, multicenter phase II investigator-initiated trial. The study aims to explore the efficacy and safety of Adebrelimab plus Trastuzumab rezetecan induction therapy in patients with stage III…
- Trial name
- NCT07778745
- Testing
- Adebrelimab, Trastuzumab rezetecan
- Volunteers
- 37 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital